New study shows SkylineDx's SKY92 test better identifies high-risk multiple myeloma patients.

A new study presented at the American Society of Hematology conference shows that SkylineDx's SKY92 test can help identify high-risk multiple myeloma patients more accurately than traditional methods. Conducted across nine U.S. cancer centers, the research found that patients with high-risk SKY92 biomarkers had worse survival rates, aiding doctors in tailoring better treatments. This advancement in personalized medicine could improve outcomes for multiple myeloma patients.

December 07, 2024
3 Articles